Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.62 |
| ▸ | BTK | Q06187 | 5/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | JAK3 | P52333 | 2/20 | 0.53 |
| ▸ | ITK | Q08881 | 2/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 3/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702263 | 0.91 | PIK3CD (0.66) | PIK3CDBTKEGFRLCKJAK3 | |
| SCHEMBL16701907 | 0.89 | PIK3CD (0.62) | PIK3CDBTKEGFRLCKJAK3 | |
| SCHEMBL16701794 | 0.88 | PIK3CD (0.61) | PIK3CDBTKEGFRLCKJAK3 | |
| SCHEMBL16701807 | 0.87 | PIK3CD (0.60) | PIK3CDBTKEGFRLCKJAK3 | |
| SCHEMBL16701712 | 0.87 | PIK3CD (0.59) | PIK3CDBTKEGFRLCKJAK3 | |
| SCHEMBL16701615 | 0.85 | PIK3CD (0.69) | PIK3CDBTKEGFRLCKJAK3 | |
| SCHEMBL16702270 | 0.85 | PIK3CD (0.60) | PIK3CDBTKEGFRLCKJAK3 | |
| SCHEMBL16701922 | 0.84 | PIK3CD (0.72) | PIK3CDBTKEGFRLCKJAK3 | |
| SCHEMBL16702425 | 0.84 | BTK (0.63) | PIK3CDBTKEGFRLCKJAK3 | |
| SCHEMBL16701925 | 0.83 | PIK3CD (0.63) | PIK3CDBTKEGFRLCKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CD 2/4885BTK 1/4885EGFR 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.